Elise Deluche1, Alison Antoine2, Thomas Bachelot3, Audrey Lardy-Cleaud2, Veronique Dieras4, Etienne Brain5, Marc Debled6, William Jacot7, Marie Ange Mouret-Reynier8, Anthony Goncalves9, Florence Dalenc10, Anne Patsouris11, Jean Marc Ferrero12, Christelle Levy13, Veronique Lorgis14, Laurence Vanlemmens15, Claudia Lefeuvre-Plesse4, Simone Mathoulin-Pelissier16, Thierry Petit17, Lionel Uwer18, Christelle Jouannaud19, Marianne Leheurteur20, Magali Lacroix-Triki21, Coralie Courtinard22, David Perol2, Mathieu Robain22, Suzette Delaloge23. 1. Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, 94800, France; Department of Medical Oncology, CHU de Limoges, France. 2. Department of Biostatistics, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, Lyon, 69008, France. 3. Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, Lyon, 69008, France. 4. Medical Oncology Department, Centre Eugéne Marquis, Avenue de La Bataille Flandres-Dunkerque, Rennes, 35000, France. 5. Department of Medical Oncology, Institut Curie, 26 Rue D'Ulm, Paris & Saint-Cloud, 75005, France. 6. Department of Medical Oncology, Institut Bergonié, 229 Cours de L'Argonne, Bordeaux, 33000, France. 7. Department of Medical Oncology, Institut Du Cancer de Montpellier, 208 Rue des Apothicaires, Montpellier, 34298, France. 8. Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, Clermont Ferrand, 63011, France. 9. Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, Marseille, 13009, France. 10. Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, Toulouse, 31059, France. 11. Department of Medical Oncology, Institut de Cancérologie de L'Ouest Nantes & Angers, 15 Rue André Boquel, Angers, 49055, France. 12. Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, Nice, 06189, France. 13. Department of Medical Oncology, Centre François Baclesse, 3 Avenue Du Général Harris, Caen, 14000, France. 14. Department of Medical Oncology, Institut de Cancérologie de Bourgogne, Dijon, 21079, France. 15. Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, Lille, 59000, France. 16. INSERM CIC1401, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, 33000, France. 17. Department of Medical Oncology, Centre Paul Strauss, 3 Rue de La Porte de L'Hôpital, Strasbourg, 67000, France. 18. Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, Vandœuvre-lès-Nancy, 54519, France. 19. Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue Du Général Koenig, Reims, 51100, France. 20. Department of Medical Oncology, Centre Henri Becquerel, Rue D'Amiens, Rouen, 76000, France. 21. Department of BioPathology, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, 94800, France. 22. Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, Paris, 75654, France. 23. Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, 94800, France. Electronic address: suzette.delaloge@gustaveroussy.fr.
Abstract
AIM: Real-world data inform the outcome comparisons and help the development of new therapeutic strategies. To this end, we aimed to describe the full characteristics and outcomes in the Epidemiological Strategy and Medical Economics (ESME) cohort, a large national contemporary observational database of patients with metastatic breast cancer (MBC). METHODS: Women aged ≥18 years with newly diagnosed MBC and who initiated MBC treatment between January 2008 and December 2016 in one of the 18 French Comprehensive Cancer Centers (N = 22,109) were included. We assessed the full patients' characteristics, first-line treatments, overall survival (OS) and first-line progression-free survival, as well as updated prognostic factors in the whole cohort and among the 3 major subtypes: hormone receptor positive and HER2-negative (HR+/HER2-, n = 13,656), HER2-positive (HER2+, n = 4017) and triple-negative (n = 2963) tumours. RESULTS: The median OS of the whole cohort was 39.5 months (95% confidence interval [CI], 38.7-40.3). Five-year OS was 33.8%. OS differed significantly between the 3 subtypes (p < 0.0001) with a median OS of 43.3 (95% CI, 42.5-44.5) in HR+/HER2-; 50.1 (95% CI, 47.6-53.1) in HER2+; and 14.8 months (95% CI, 14.1-15.5) in triple-negative subgroups, respectively. Beyond performance status, the following variables had a constant significant negative prognostic impact on OS in the whole cohort and among subtypes: older age at diagnosis of metastases (except for the triple-negative subtype), metastasis-free interval between 6 and 24 months, presence of visceral metastases and number of metastatic sites ≥ 3. CONCLUSIONS: The ESME program represents a unique large-scale real-life cohort on MBC. This study highlights important situations of high medical need within MBC patients. DATABASE REGISTRATION: clinicaltrials.gov Identifier NCT032753.
AIM: Real-world data inform the outcome comparisons and help the development of new therapeutic strategies. To this end, we aimed to describe the full characteristics and outcomes in the Epidemiological Strategy and Medical Economics (ESME) cohort, a large national contemporary observational database of patients with metastatic breast cancer (MBC). METHODS:Women aged ≥18 years with newly diagnosed MBC and who initiated MBC treatment between January 2008 and December 2016 in one of the 18 French Comprehensive Cancer Centers (N = 22,109) were included. We assessed the full patients' characteristics, first-line treatments, overall survival (OS) and first-line progression-free survival, as well as updated prognostic factors in the whole cohort and among the 3 major subtypes: hormone receptor positive and HER2-negative (HR+/HER2-, n = 13,656), HER2-positive (HER2+, n = 4017) and triple-negative (n = 2963) tumours. RESULTS: The median OS of the whole cohort was 39.5 months (95% confidence interval [CI], 38.7-40.3). Five-year OS was 33.8%. OS differed significantly between the 3 subtypes (p < 0.0001) with a median OS of 43.3 (95% CI, 42.5-44.5) in HR+/HER2-; 50.1 (95% CI, 47.6-53.1) in HER2+; and 14.8 months (95% CI, 14.1-15.5) in triple-negative subgroups, respectively. Beyond performance status, the following variables had a constant significant negative prognostic impact on OS in the whole cohort and among subtypes: older age at diagnosis of metastases (except for the triple-negative subtype), metastasis-free interval between 6 and 24 months, presence of visceral metastases and number of metastatic sites ≥ 3. CONCLUSIONS: The ESME program represents a unique large-scale real-life cohort on MBC. This study highlights important situations of high medical need within MBC patients. DATABASE REGISTRATION: clinicaltrials.gov Identifier NCT032753.
Authors: M Bringuier; M Carton; C Levy; A Patsouris; D Pasquier; M Debled; O Rigal; W Jacot; A Gonçalves; I Desmoulins; T De La Motte Rouge; T Bachelot; J-M Ferrero; J-C Eymard; M Ung; M-A Mouret-Reynier; T Petit; M Chevrot; L Uwer; C Courtinard; J-S Frenel; A Vianzone; C Baldini Journal: Breast Cancer Res Treat Date: 2022-01-05 Impact factor: 4.872
Authors: Marissa Meegdes; Sandra M E Geurts; Frans L G Erdkamp; Marcus Wouter Dercksen; Birgit E P J Vriens; Kirsten N A Aaldering; Manon J A E Pepels; Linda M H van de Winkel; Nathalie J A Teeuwen; Maaike de Boer; Vivianne C G Tjan-Heijnen Journal: Int J Cancer Date: 2021-09-14 Impact factor: 7.316
Authors: Peter A Fasching; Siddhartha Yadav; Chunling Hu; Marius Wunderle; Lothar Häberle; Steven N Hart; Matthias Rübner; Eric C Polley; Kun Y Lee; Rohan D Gnanaolivu; Peyman Hadji; Hanna Hübner; Hans Tesch; Johannes Ettl; Friedrich Overkamp; Michael P Lux; Arif B Ekici; Bernhard Volz; Sabrina Uhrig; Diana Lüftner; Markus Wallwiener; Volkmar Müller; Erik Belleville; Michael Untch; Hans-Christian Kolberg; Matthias W Beckmann; André Reis; Arndt Hartmann; Wolfgang Janni; Pauline Wimberger; Florin-Andrei Taran; Tanja N Fehm; Diethelm Wallwiener; Sara Y Brucker; Andreas Schneeweiss; Andreas D Hartkopf; Fergus J Couch Journal: J Clin Oncol Date: 2021-03-29 Impact factor: 44.544
Authors: Jennifer L Caswell-Jin; Alison Callahan; Natasha Purington; Summer S Han; Haruka Itakura; Esther M John; Douglas W Blayney; George W Sledge; Nigam H Shah; Allison W Kurian Journal: JCO Clin Cancer Inform Date: 2021-05